A detailed history of Fox Run Management, L.L.C. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 12,084 shares of GH stock, worth $529,883. This represents 0.07% of its overall portfolio holdings.

Number of Shares
12,084
Holding current value
$529,883
% of portfolio
0.07%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$20.2 - $38.11 $244,096 - $460,521
12,084 New
12,084 $369,000
Q1 2024

May 13, 2024

BUY
$17.13 - $26.91 $129,519 - $203,466
7,561 Added 41.79%
25,652 $529,000
Q4 2023

Feb 13, 2024

BUY
$21.58 - $29.5 $390,403 - $533,684
18,091 New
18,091 $489,000
Q2 2023

Aug 11, 2023

SELL
$20.94 - $38.01 $455,340 - $826,527
-21,745 Reduced 47.78%
23,761 $850,000
Q1 2023

May 12, 2023

BUY
$22.92 - $33.76 $602,543 - $887,516
26,289 Added 136.8%
45,506 $1.07 Million
Q4 2022

Feb 07, 2023

BUY
$25.44 - $59.78 $189,706 - $445,779
7,457 Added 63.41%
19,217 $522,000
Q3 2022

Nov 07, 2022

BUY
$43.66 - $61.0 $235,545 - $329,095
5,395 Added 84.76%
11,760 $633,000
Q2 2022

Aug 12, 2022

BUY
$28.82 - $77.35 $76,661 - $205,750
2,660 Added 71.79%
6,365 $257,000
Q1 2022

May 10, 2022

BUY
$48.25 - $100.49 $178,766 - $372,315
3,705 New
3,705 $245,000
Q3 2020

Oct 29, 2020

SELL
$80.32 - $111.8 $343,127 - $477,609
-4,272 Closed
0 $0
Q2 2020

Jul 31, 2020

BUY
$60.49 - $97.5 $36,294 - $58,500
600 Added 16.34%
4,272 $347,000
Q1 2020

May 08, 2020

SELL
$59.04 - $88.81 $22,376 - $33,658
-379 Reduced 9.36%
3,672 $256,000
Q4 2019

Feb 14, 2020

BUY
$59.49 - $82.78 $240,993 - $335,341
4,051 New
4,051 $317,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $4.48B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.